Cormorant Asset Management, LP Nektar Therapeutics Call Options Transaction History

Cormorant Asset Management, LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $32.8 Million - $61.1 Million	-1,078,400 Reduced 81.18%	250,000 $8.22 Million
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $23.2 Million - $34.2 Million	-500,000 Reduced 27.35%	1,328,400 $81 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $13.8 Million - $31.1 Million	297,500 Added 19.43%	1,828,400 $89.3 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $44.8 Million - $84.7 Million	780,900 Added 104.12%	1,530,900 $163 Million
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $17.3 Million - $45.4 Million	750,000	750,000 $44.8 Million

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.